Gunderson Dettmer advised Histogenics Corporation on a follow-on public offering underwritten public offering of 26,155,000 shares of its common stock and warrants to purchase up to 19,616,250 shares of common stock, at a combined purchase price of $0.65 per share of common stock and accompanying warrant, for a total of $17,000,750.00 in aggregate gross proceeds. Corporate partner Marc Dupre, of counsel Keith Scherer, and associates Albert Vanderlaan and Naomi Smith led the team advising Histogenics.

Canaccord Genuity LLC and BTIG, LLC acted as the joint book-running managers for the offering. H.C. Wainwright & Co., LLC acted as the co-manager for the offering.

Histogenics, which trades on The Nasdaq Capital Market under the ticker symbol “HSGX,” is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function.